Opportunities and challenges in the discovery of new central nervous system drugs

Annals of the New York Academy of Sciences

Volumn 1144, Issue , 2008, Pages 243-250

  Krause, James E ^a   Chenard, Bertrand L ^a  

^a ARMGO Pharma Inc   (United States)

Author keywords

Drug discovery; FDA; Positron emission tomography; Receptor occupancy; Systems biology

Indexed keywords

APREPITANT; ATOMOXETINE; CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE UPTAKE INHIBITOR; DULOXETINE; FLUOXETINE; G PROTEIN COUPLED RECEPTOR; MIDAZOLAM; NATALIZUMAB; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y5 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR ANTAGONIST; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OMEGA CONOTOXIN MVIIA; RAMELTEON; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL CELL; BIOTECHNOLOGY; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; DRUG APPROVAL; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; RECEPTOR OCCUPANCY;

EID: 56649095991     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1418.024     Document Type: Conference Paper

References (20)

1. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
2. Hegde, S. & J. Carter. 2004. To market, to market 2003. Annu. Rep. Med. Chem. 39 : 337 368.
3. Hegde, S. & S.M. Schmidt. 2005. To market, to market 2004. Annu. Rep. Med. Chem. 40 : 443 473.
4. Hegde, S. & S.M. Schmidt. 2006. To market, to market 2005. Annu. Rep. Med. Chem. 41 : 439 447.
5. Hegde, S. & S.M. Schmidt. 2007. To market, to market 2006. Annu. Rep. Med. Chem. 42 : 505 554.
6. Prozac Label : http://www.prozac.com/common_pages/ prescribing_information.jsp
7. Milne, G.M. 2003. Pharmaceutical productivity - The imperative for new paradigms. Annu. Rep. Med. Chem. 38 : 383 396.
8. Gloriam, D.E. et al. 2007. The G protein-coupled receptor subset of the rat genome. BMC Genomics 8 : 1 17.
9. Lagerstrom, M.C. & H.B. Schioth. 2008. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Disc. 7 : 339 358.
10. Bondensgaard, K. et al. 2004. Recognition of privileged structures by G-protein coupled receptors. J. Med. Chem. 47 : 888 899.
11. Van de Waterbeemd, H. & E. Gifford. 2003. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Disc. 2 : 192 204.
12. Patel, S. et al. 2005. Screening cascade and development of potential Positron Emission Tomography radiotracers for mGluR5: in vitro and in vivo characterization. Mol. Imaging Biol. 7 : 314 323.
13. Erondu, N. et al. 2006. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 4 : 275 282.
14. Lipinski, C.A. et al. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 : 3 36.
15. Cuatrecasas, P. 2006. Drug discovery in jeopardy. J. Clin. Invest. 116 : 2837 2842.
16. http://www.fda.gov/oc/initiatives/criticalpath/
17. van Herwaarden, A.E. et al. 2007. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest. 117 : 3583 3592.
18. van Waterschoot, R.A. et al. 2008. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol. Pharmacol. 73 : 1029 1036.
19. Foster-Schubert, K.E. & D.E. Cummings. 2006. Emerging therapeutic strategies for obesity. Endocr. Rev. 27 : 779 793.
20. Ahnaou A. et al. 2008. Blocking melanin-concentrating hormone MCH1 receptor affects rat sleep-wake architecture. Eur. J. Pharmacol. 579 : 177 188.